|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 280.20 USD | -0.38% |
|
-13.37% | -29.53% |
| 06:35am | Alnylam Initiates Mid-Stage Study of Mivelsiran in Down Syndrome-Associated Alzheimer's | MT |
| 07-14 | Alnylam Pharmaceuticals' Q2 Results to Determine 2026 Revenue Outlook, BofA Securities Says | MT |
| Market Cap | 37.55B 32.83B 30.29B 27.84B 52.75B 3,613B 53.65B 362B 142B 1,766B 141B 138B 6,087B | P/E 2026 * |
37.2x | P/E 2027 * | 26.5x |
|---|---|---|---|---|---|
| Enterprise Value | 34.66B 30.3B 27.96B 25.7B 48.69B 3,335B 49.52B 334B 131B 1,630B 130B 127B 5,619B | EV / Sales 2026 * |
6.19x | EV / Sales 2027 * | 4.53x |
| Free-Float |
99.82% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Alnylam Pharmaceuticals, Inc.
| 1 day | -0.38% | ||
| 1 week | -13.37% | ||
| Current month | -6.91% | ||
| 1 month | -2.63% | ||
| 3 months | -15.94% | ||
| 6 months | -22.00% | ||
| Current year | -29.53% |
| 1 week | 279.41 |  | 380 |
| 1 month | 273.11 | | 380 |
| Current year | 273.11 | | 427.05 |
| 1 year | 273.11 | | 495.55 |
| 3 years | 141.98 | | 495.55 |
| 5 years | 117.58 | | 495.55 |
| 10 years | 31.38 | | 495.55 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 63 | 2021-12-31 | |
Jeffrey Poulton
DFI | Director of Finance/CFO | 58 | 2019-08-12 |
| Chief Tech/Sci/R&D Officer | - | 2023-03-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Dennis Ausiello
BRD | Director/Board Member | 80 | 2012-04-22 |
Amy Schulman
CHM | Chairman | 65 | 2023-01-04 |
David Pyott
BRD | Director/Board Member | 72 | 2015-12-17 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 05-31 | Fiscal year | Director | 11,490 | 0.0086% | ||
| 05-31 | Free | Director | 4,393 | 0.0033% | ||
| 05-19 | Free | Director | 2,112 | 0.0016% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.38% | -13.37% | -9.93% | +38.16% | 37.55B | |
| -0.62% | -5.80% | +48.41% | +156.15% | 1,028B | |
| -1.63% | -4.77% | +61.65% | +57.68% | 611B | |
| +1.36% | -2.44% | +32.30% | +82.89% | 432B | |
| +0.98% | -1.40% | +29.49% | +23.12% | 323B | |
| -0.34% | -3.10% | +27.00% | +43.66% | 277B | |
| +1.63% | -11.76% | +19.72% | +23.20% | 257B | |
| +3.39% | +2.29% | -23.68% | -38.33% | 217B | |
| +0.61% | -2.67% | +22.44% | +57.20% | 192B | |
| +1.53% | -2.51% | +21.41% | +70.90% | 161B | |
| Average | +0.72% | -5.97% | +22.88% | +51.46% | 353.59B | |
| Weighted average by Cap. | +0.25% | -5.59% | +35.56% | +77.11% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 5.6B 4.9B 4.52B 4.15B 7.87B 539B 8B 53.92B 21.16B 263B 21.03B 20.57B 908B | 7.26B 6.35B 5.86B 5.38B 10.2B 699B 10.38B 69.92B 27.43B 342B 27.27B 26.67B 1,177B |
| Net income | 1.01B 884M 815M 750M 1.42B 97.27B 1.44B 9.73B 3.82B 47.55B 3.8B 3.71B 164B | 1.47B 1.29B 1.19B 1.09B 2.07B 142B 2.1B 14.17B 5.56B 69.2B 5.53B 5.4B 239B |
| Net Debt | -2.89B -2.53B -2.33B -2.14B -4.06B -278B -4.13B -27.83B -10.92B -136B -10.86B -10.62B -469B | -4.65B -4.07B -3.75B -3.45B -6.53B -447B -6.64B -44.78B -17.57B -219B -17.46B -17.08B -754B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-15 | US$280.22 | -0.37% | 331,492 |
| 26-07-14 | US$281.26 | -2.36% | 1,093,297 |
| 26-07-13 | US$288.06 | -3.58% | 2,682,652 |
| 26-07-10 | US$298.76 | -4.49% | 2,538,292 |
| 26-07-09 | US$312.79 | -3.31% | 5,864,993 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ALNY Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition